{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:47:15Z","timestamp":1788094035069,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11864-025-01332-6","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:18:15Z","timestamp":1748229495000},"page":"587-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alternate Dosing Regimens for Vismodegib: A Literature Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Kevin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Ho-Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conway C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"1332_CR1","doi-asserted-by":"crossref","unstructured":"1. Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-9.","DOI":"10.1056\/NEJMoa1113713"},{"key":"1332_CR2","doi-asserted-by":"crossref","unstructured":"2. Tang JY, et al.\u00a0Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-8.","DOI":"10.1056\/NEJMoa1113538"},{"key":"1332_CR3","doi-asserted-by":"crossref","unstructured":"3. Basset-S\u00e9guin N, et al.\u00a0Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u2013348.","DOI":"10.1016\/j.ejca.2017.08.022"},{"key":"1332_CR4","doi-asserted-by":"crossref","unstructured":"4. Lacouture ME, et al.\u00a0Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10): 1218\u20131229.","DOI":"10.1634\/theoncologist.2016-0186"},{"key":"1332_CR5","doi-asserted-by":"crossref","unstructured":"5. Lorusso PM, et al.\u00a0Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774-82.","DOI":"10.1158\/1078-0432.CCR-11-0972"},{"key":"1332_CR6","doi-asserted-by":"crossref","unstructured":"6. Woltsche N, et al.\u00a0Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience. J Eur Acad Dermatol Venereol. 2019;33(4):e144-e145.","DOI":"10.1111\/jdv.15367"},{"key":"1332_CR7","doi-asserted-by":"crossref","unstructured":"7. Scalvenzi M, et al.\u00a0Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33(4): e145-e147.","DOI":"10.1111\/jdv.15469"},{"key":"1332_CR8","doi-asserted-by":"crossref","unstructured":"8. Wong C, Poblete-Lopez C, Vidimos A.\u00a0Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: a retrospective case series. J Am Acad Dermatol. 2020;82(6):1539\u20131542.","DOI":"10.1016\/j.jaad.2020.02.050"},{"key":"1332_CR9","doi-asserted-by":"crossref","unstructured":"9. Scalvenzi M, et al.\u00a0Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity. Dermatol Ther (Heidelb). 2020;10(3):465\u2013468.","DOI":"10.1007\/s13555-020-00371-1"},{"key":"1332_CR10","doi-asserted-by":"crossref","unstructured":"10. Routt E, Ratner D.\u00a0Outcomes for basal cell carcinoma treated with vismodegib extended alternate day dosing. Dermatol Surg. 2020;46(8): 1109\u20131112.","DOI":"10.1097\/DSS.0000000000001985"},{"key":"1332_CR11","doi-asserted-by":"crossref","unstructured":"11. Valenzuela-O\u00f1ate CA, et al.\u00a0Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice. Dermatol Ther. 2020;33(4):e13540.","DOI":"10.1111\/dth.13540"},{"key":"1332_CR12","doi-asserted-by":"crossref","unstructured":"12. Yoon J.\u00a0Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma. JAAD Case Rep. 2021;7:107\u2013109.","DOI":"10.1016\/j.jdcr.2020.11.014"},{"key":"1332_CR13","doi-asserted-by":"crossref","unstructured":"13. Kim J, et al.\u00a0Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388\u2013399.","DOI":"10.1016\/j.ccr.2010.02.027"},{"key":"1332_CR14","doi-asserted-by":"crossref","unstructured":"14. Yoon J, Apicelli AJ, Pavlopoulos TV.\u00a0Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib. JAAD Case Rep. 2018;4(1):10\u201312.","DOI":"10.1016\/j.jdcr.2017.11.001"},{"key":"1332_CR15","doi-asserted-by":"crossref","unstructured":"15. de Perosanz-Lobo D, et al.\u00a0Hepatotoxicity associated with vismodegib: could dose reduction be an effective management? Dermatol Surg. 2021;47(7): 1006\u20131007.","DOI":"10.1097\/DSS.0000000000002924"},{"key":"1332_CR16","doi-asserted-by":"crossref","unstructured":"16. Sofen H, et al.\u00a0A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73(1): 99\u2013105.e1.","DOI":"10.1016\/j.jaad.2015.03.013"},{"key":"1332_CR17","doi-asserted-by":"crossref","unstructured":"17. Dr\u00e9no B, et al.\u00a0Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u2013412.","DOI":"10.1016\/S1470-2045(17)30072-4"},{"key":"1332_CR18","doi-asserted-by":"crossref","unstructured":"18. Schadendorf D, et al.\u00a0Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study. J Eur Acad Dermatol Venereol. 2020;34(9):e526-e529.","DOI":"10.1111\/jdv.16446"},{"key":"1332_CR19","doi-asserted-by":"crossref","unstructured":"19. Becker LR, et al.\u00a0A novel alternate dosing of vismodegib for treatment of patients with advanced basal cell carcinomas. JAMA Dermatol. 2017;153(4):321\u2013322.","DOI":"10.1001\/jamadermatol.2016.5058"},{"key":"1332_CR20","doi-asserted-by":"crossref","unstructured":"20. Villani A, et al.\u00a0Reply to: \u201cComparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: a retrospective case series\u201d. J Am Acad Dermatol. 2020;83(3):e201-e202.","DOI":"10.1016\/j.jaad.2020.03.124"},{"key":"1332_CR21","doi-asserted-by":"crossref","unstructured":"21. Yang X, Dinehart SM.\u00a0Intermittent vismodegib therapy in basal cell nevus syndrome. JAMA Dermatol. 2016;152(2):223-4.","DOI":"10.1001\/jamadermatol.2015.3210"},{"key":"1332_CR22","doi-asserted-by":"crossref","unstructured":"22. Tronconi MC, et al.\u00a0Tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced basal cell carcinoma: a pilot analysis. Front Oncol. 2020;10:563404.","DOI":"10.3389\/fonc.2020.563404"},{"key":"1332_CR23","doi-asserted-by":"crossref","unstructured":"23. Russo F, et al.\u00a0Long-term efficacy of a Vismodegib regime including a 1-week drug holiday every month in two patients with Gorlin Goltz syndrome. Dermatol Ther. 2022;35(3):e15293.","DOI":"10.1111\/dth.15293"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01332-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:13:09Z","timestamp":1752811989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01332-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01332-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"14 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}